BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia

Molecular Cell

Volumn 58, Issue 6, 2015, Pages 1028-1039

  Roe, Jae Seok ^a   Mercan, Fatih ^a   Rivera, Keith ^a   Pappin, Darryl J ^a   Vakoc, Christopher R ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; BROMODOMAIN CONTAINING PROTEIN 4; BROMODOMAIN INHIBITOR; E1A ASSOCIATED P300 PROTEIN; LYSINE; PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; BRD4 PROTEIN, MOUSE; CCAAT ENHANCER BINDING PROTEIN BETA; ERG PROTEIN, MOUSE; FLI1 PROTEIN, MOUSE; HISTONE; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN BINDING; PROTEIN C MYB; PROTO-ONCOGENE PROTEIN SPI-1; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR FLI 1; TRIAZOLE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CHROMATIN; ENHANCER REGION; HEMATOPOIESIS; HISTONE ACETYLATION; HUMAN; NONHUMAN; NUCLEOSOME; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; 3T3 CELL LINE; ACETYLATION; ACUTE DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; HEMATOPOIETIC SYSTEM; METABOLISM; MOUSE; MYELOID LEUKEMIA; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

ACETYLATION; ACUTE DISEASE; ANIMALS; AZEPINES; BLOTTING, WESTERN; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HEMATOPOIETIC SYSTEM; HISTONES; HUMANS; LEUKEMIA, MYELOID; MICE; NIH 3T3 CELLS; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROTEIN BINDING; PROTO-ONCOGENE PROTEIN C-FLI-1; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MYB; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRIAZOLES;

EID: 84937639611     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2015.04.011     Document Type: Article

References (55)

1. Aikawa Y., Yamagata K., Katsumoto T., Shima Y., Shino M., Stanley E.R., Cleary M.L., Akashi K., Tenen D.G., Kitabayashi I. Essential role of PU.1 in maintenance of mixed lineage leukemia-associated leukemic stem cells. Cancer Sci. 2014, 106:227-236.
2. Bailey T.L., Boden M., Buske F.A., Frith M., Grant C.E., Clementi L., Ren J., Li W.W., Noble W.S. MEME SUITE: tools for motif discovery and searching. Nucleic Acids Res. 2009, 37:W202-W208.
3. Blobel G.A. CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood 2000, 95:745-755.
4. Bolden J.E., Tasdemir N., Dow L.E., van Es J.H., Wilkinson J.E., Zhao Z., Clevers H., Lowe S.W. Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition. Cell Rep. 2014, 8:1919-1929.
5. Borah J.C., Mujtaba S., Karakikes I., Zeng L., Muller M., Patel J., Moshkina N., Morohashi K., Zhang W., Gerona-Navarro G., et al. A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem. Biol. 2011, 18:531-541.
6. Bowers E.M., Yan G., Mukherjee C., Orry A., Wang L., Holbert M.A., Crump N.T., Hazzalin C.A., Liszczak G., Yuan H., et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem. Biol. 2010, 17:471-482.
7. Calabretta B., Sims R.B., Valtieri M., Caracciolo D., Szczylik C., Venturelli D., Ratajczak M., Beran M., Gewirtz A.M. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. Proc. Natl. Acad. Sci. USA 1991, 88:2351-2355.
8. Chapuy B., McKeown M.R., Lin C.Y., Monti S., Roemer M.G., Qi J., Rahl P.B., Sun H.H., Yeda K.T., Doench J.G., et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 2013, 24:777-790.
9. Chen H., Ray-Gallet D., Zhang P., Hetherington C.J., Gonzalez D.A., Zhang D.E., Moreau-Gachelin F., Tenen D.G. PU.1 (Spi-1) autoregulates its expression in myeloid cells. Oncogene 1995, 11:1549-1560.
10. Dai P., Akimaru H., Tanaka Y., Hou D.X., Yasukawa T., Kanei-Ishii C., Takahashi T., Ishii S. CBP as a transcriptional coactivator of c-Myb. Genes Dev. 1996, 10:528-540.
11. Dawson M.A., Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012, 150:12-27.
12. Dawson M.A., Prinjha R.K., Dittmann A., Giotopoulos G., Bantscheff M., Chan W.I., Robson S.C., Chung C.W., Hopf C., Savitski M.M., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478:529-533.
13. Dawson M.A., Gudgin E.J., Horton S.J., Giotopoulos G., Meduri E., Robson S., Cannizzaro E., Osaki H., Wiese M., Putwain S., et al. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia 2014, 28:311-320.
14. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
15. Dey A., Chitsaz F., Abbasi A., Misteli T., Ozato K. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc. Natl. Acad. Sci. USA 2003, 100:8758-8763.
16. Dhalluin C., Carlson J.E., Zeng L., He C., Aggarwal A.K., Zhou M.M. Structure and ligand of a histone acetyltransferase bromodomain. Nature 1999, 399:491-496.
17. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
18. Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P., Barsyte-Lovejoy D., Felletar I., Volkmer R., Müller S., Pawson T., et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 2012, 149:214-231.
19. Goodman R.H., Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 2000, 14:1553-1577.
20. Gröschel S., Sanders M.A., Hoogenboezem R., de Wit E., Bouwman B.A., Erpelinck C., van der Velden V.H., Havermans M., Avellino R., van Lom K., et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell 2014, 157:369-381.
21. Gu W., Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997, 90:595-606.
22. Hay D.A., Fedorov O., Martin S., Singleton D.C., Tallant C., Wells C., Picaud S., Philpott M., Monteiro O.P., Rogers C.M., et al. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J. Am. Chem. Soc. 2014, 136:9308-9319.
23. Jang M.K., Mochizuki K., Zhou M., Jeong H.S., Brady J.N., Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 2005, 19:523-534.
24. Jin S., Zhao H., Yi Y., Nakata Y., Kalota A., Gewirtz A.M. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J. Clin. Invest. 2010, 120:593-606.
25. Jones L.C., Lin M.L., Chen S.S., Krug U., Hofmann W.K., Lee S., Lee Y.H., Koeffler H.P. Expression of C/EBPbeta from the C/ebpalpha gene locus is sufficient for normal hematopoiesis in vivo. Blood 2002, 99:2032-2036.
26. Kruse E.A., Loughran S.J., Baldwin T.M., Josefsson E.C., Ellis S., Watson D.K., Nurden P., Metcalf D., Hilton D.J., Alexander W.S., Kile B.T. Dual requirement for the ETS transcription factors Fli-1 and Erg in hematopoietic stem cells and the megakaryocyte lineage. Proc. Natl. Acad. Sci. USA 2009, 106:13814-13819.
27. Lamonica J.M., Deng W., Kadauke S., Campbell A.E., Gamsjaeger R., Wang H., Cheng Y., Billin A.N., Hardison R.C., Mackay J.P., Blobel G.A. Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes. Proc. Natl. Acad. Sci. USA 2011, 108:E159-E168.
28. Lovén J., Hoke H.A., Lin C.Y., Lau A., Orlando D.A., Vakoc C.R., Bradner J.E., Lee T.I., Young R.A. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153:320-334.
29. Lu C., Thompson C.B. Metabolic regulation of epigenetics. Cell Metab. 2012, 16:9-17.
30. Mair B., Kubicek S., Nijman S.M. Exploiting epigenetic vulnerabilities for cancer therapeutics. Trends Pharmacol. Sci. 2014, 35:136-145.
31. McManus K.J., Hendzel M.J. Quantitative analysis of CBP- and P300-induced histone acetylations in vivo using native chromatin. Mol. Cell. Biol. 2003, 23:7611-7627.
32. Mertz J.A., Conery A.R., Bryant B.M., Sandy P., Balasubramanian S., Mele D.A., Bergeron L., Sims R.J. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. USA 2011, 108:16669-16674.
33. Mink S., Haenig B., Klempnauer K.H. Interaction and functional collaboration of p300 and C/EBPbeta. Mol. Cell. Biol. 1997, 17:6609-6617.
34. Morinière J., Rousseaux S., Steuerwald U., Soler-López M., Curtet S., Vitte A.L., Govin J., Gaucher J., Sadoul K., Hart D.J., et al. Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. Nature 2009, 461:664-668.
35. Nicodeme E., Jeffrey K.L., Schaefer U., Beinke S., Dewell S., Chung C.W., Chandwani R., Marazzi I., Wilson P., Coste H., et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468:1119-1123.
36. Ohlsson E., Hasemann M.S., Willer A., Lauridsen F.K., Rapin N., Jendholm J., Porse B.T. Initiation of MLL-rearranged AML is dependent on C/EBPα. J. Exp. Med. 2014, 211:5-13.
37. Ott C.J., Kopp N., Bird L., Paranal R.M., Qi J., Bowman T., Rodig S.J., Kung A.L., Bradner J.E., Weinstock D.M. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012, 120:2843-2852.
38. Ramsey S.A., Knijnenburg T.A., Kennedy K.A., Zak D.E., Gilchrist M., Gold E.S., Johnson C.D., Lampano A.E., Litvak V., Navarro G., et al. Genome-wide histone acetylation data improve prediction of mammalian transcription factor binding sites. Bioinformatics 2010, 26:2071-2075.
39. Rosenbauer F., Tenen D.G. Transcription factors in myeloid development: balancing differentiation with transformation. Nat. Rev. Immunol. 2007, 7:105-117.
40. Shi J., Vakoc C.R. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell 2014, 54:728-736.
41. Shi J., Whyte W.A., Zepeda-Mendoza C.J., Milazzo J.P., Shen C., Roe J.S., Minder J.L., Mercan F., Wang E., Eckersley-Maslin M.A., et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev. 2013, 27:2648-2662.
42. Shi J., Wang Y., Zeng L., Wu Y., Deng J., Zhang Q., Lin Y., Li J., Kang T., Tao M., et al. Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. Cancer Cell 2014, 25:210-225.
43. Stonestrom A.J., Hsu S.C., Jahn K.S., Huang P., Keller C.A., Giardine B.M., Kadauke S., Campbell A.E., Evans P., Hardison R.C., Blobel G.A. Functions of BET proteins in erythroid gene expression. Blood 2015, 125:2825-2834.
44. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
45. Szerlong H.J., Prenni J.E., Nyborg J.K., Hansen J.C. Activator-dependent p300 acetylation of chromatin in vitro: enhancement of transcription by disruption of repressive nucleosome-nucleosome interactions. J. Biol. Chem. 2010, 285:31954-31964.
46. Wajapeyee N., Malonia S.K., Palakurthy R.K., Green M.R. Oncogenic RAS directs silencing of tumor suppressor genes through ordered recruitment of transcriptional repressors. Genes Dev. 2013, 27:2221-2226.
47. Wang L., Gural A., Sun X.J., Zhao X., Perna F., Huang G., Hatlen M.A., Vu L., Liu F., Xu H., et al. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 2011, 333:765-769.
48. Wang E., Kawaoka S., Yu M., Shi J., Ni T., Yang W., Zhu J., Roeder R.G., Vakoc C.R. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia. Proc. Natl. Acad. Sci. USA 2013, 110:3901-3906.
49. Wu S.Y., Lee A.Y., Lai H.T., Zhang H., Chiang C.M. Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol. Cell 2013, 49:843-857.
50. Yamamoto H., Kihara-Negishi F., Yamada T., Hashimoto Y., Oikawa T. Physical and functional interactions between the transcription factor PU.1 and the coactivator CBP. Oncogene 1999, 18:1495-1501.
51. Yang Z., Yik J.H., Chen R., He N., Jang M.K., Ozato K., Zhou Q. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell 2005, 19:535-545.
52. Zhang W., Prakash C., Sum C., Gong Y., Li Y., Kwok J.J., Thiessen N., Pettersson S., Jones S.J., Knapp S., et al. Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J. Biol. Chem. 2012, 287:43137-43155.
53. Zuber J., McJunkin K., Fellmann C., Dow L.E., Taylor M.J., Hannon G.J., Lowe S.W. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nat. Biotechnol. 2011, 29:79-83.
54. Zuber J., Rappaport A.R., Luo W., Wang E., Chen C., Vaseva A.V., Shi J., Weissmueller S., Fellmann C., Taylor M.J., et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 2011, 25:1628-1640.
55. Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., Magoon D., Qi J., Blatt K., Wunderlich M., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.